News

While various immunotherapies work through different mechanisms, they are all designed to enhance the immune system’s ability to recognize and target cancer cells. Pembrolizumab does so by binding and inhibiting PD-1, a protein that normally protects the body from attacking itself.

The newly released 2021 WHO Classification of Tumors of the Central Nervous System (CNS) introduces major changes that advance the role of molecular profiling in CNS tumor classification and includes many new pediatric brain tumor subtypes.

Previous immunotherapies like CAR T cells were designed to target glioblastoma cells, but were only effective in killing a portion of the cells – leaving some cancer cells behind, and allowing for tumor recurrence.

A passionate social entrepreneur and philanthropist, Sheri Sobrato Brisson has dedicated her career and resources to supporting children and teens during periods of emotional distress.

The UCSF Brain Tumor Center is leading a new randomized, double-blind, placebo-controlled, phase 3 clinical trial of enzastaurin combined with temozolomide and radiation therapy in patients with newly diagnosed gliobla